Diving for drugs: Tunicate anticancer compounds

Drug Discovery Today

Volumn 17, Issue 11-12, 2012, Pages 636-648

  Cooper, Edwin L ^a   Yao, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 METHYLEUDISTOMIDIN C; 2 METHYLEUDISTOMIN D; 2 METHYLEUDISTOMIN J; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALKALOID DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPENTENONE DERIVATIVE; CYTOTOXIC AGENT; DICHLOROMETHANE; HATERUMAIMIDE F; HATERUMAIMIDE G; HATERUMAIMIDE H; HATERUMAIMIDE I; HATERUMAIMIDE J; HATERUMAIMIDE K; HATERUMAIMIDE N; HATERUMAIMIDE O; HATERUMAIMIDE P; HATERUMAIMIDE Q; LISSOCLIBADIN; LISSOCLINOLIDE; LISSOCLINOTOXIN; MOLLAMIDE B; MOLLAMIDE C; PIBOCIN B; PLANT MEDICINAL PRODUCT; SHISHIJIMICIN A; SHISHIJIMICIN B; SHISHIJIMICIN C; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL DEATH; CELL DIVISION; CELL FUNCTION; CELL PROLIFERATION; CELL SPECIFICITY; CELL VIABILITY; COLORIMETRY; CYTOTOXICITY; DRUG DESIGN; DRUG INDUSTRY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; GROWTH INHIBITION; HUMAN; MEDICINAL PLANT; NATURAL KILLER CELL; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MARINE BIOLOGY; STRUCTURE-ACTIVITY RELATIONSHIP; UROCHORDATA;

EID: 84861651888     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.02.006     Document Type: Review

References (92)

1. N. Vella 'Genetic profiling' and ovarian cancer therapy Mol. Med. Rep. 4 2011 771 777 (review)
2. G. Schwartsmann Marine organisms as a source of new anticancer agents Lancet Oncol. 2 2001 221 225
3. K.L. Rinehart Antitumor compounds from tunicates Med. Res. Rev. 20 1999 1 27
4. B. Haefner Drugs from the deep: marine natural products as drug candidates Drug Discov. Today 8 2003 536 544
5. N.L. Segraves Comparison of fascaplysin and related alkaloids: a study of structures, cytotoxicities, and sources J. Nat. Prod. 67 2004 783 792
6. M. Takagi JBIR-66, a new metabolite isolated from tunicate-derived Saccharopolyspora sp. SS081219JE-28 Biosci. Biotechnol. Biochem. 74 2010 2355 2357
7. E. Schmidt Genetic evidence supports secondary metabolic diversity in Prochloron spp., the cyanobacterial symbiont of a tropical ascidian J. Nat. Prod. 67 2004 1341 1345
8. C. Cuevas Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B Org. Lett. 2 2000 2545 2548
9. A. Mayer Marine pharmacology in 2007-8: marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneous mechanisms of action Comp. Biochem. Physiol. C: Toxicol. Pharmacol. 153 2011 191 222
10. C. Le Tourneau Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison Curr. Pharm. Des. 13 2007 3427 3439
11. I. Manzanares Advances in the chemistry and pharmacology of ecteinascidins, a promising new class of anti-cancer agents Curr. Med. Chem. Anticancer Agents 1 2001 257 276
12. D.D. Baker, and K.A. Alvi Small-molecule natural products: new structures, new activities Curr. Opin. Biotechnol. 15 2004 576 583
13. Q. Song Marine Biotechnology 2011 Hindawi Publishing Corp.
14. E.L. Cooper Bioprospecting: a CAM Frontier Evid. Based Complement. Alternat. Med. 2 2005 1 3
15. J. Robert Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates Dev. Comp. Immunol. 34 2010 915 925
16. E.L. Cooper, and N. Parrinello Immunodefense in tunicates: cells and molecules H. Sawada, H. Yokosawa, C.C. Lambert, The Biology of Ascidians 2001 Springer-Verlag 383 394
17. V. Arizza A lytic mechanism based on soluble phospholypases A2 (sPLA2) and β-galactoside specific lectins is exerted by Ciona intestinalis (ascidian) unilocular refractile hemocytes against K562 cell line and mammalian erythrocytes Fish Shellfish Immunol. 30 2011 1014 1023
18. M.S. Ramasamy, and S. Manikandan Novel pharmacological targets from Indian cone snails Mini Rev. Med. Chem. 11 2011 125 130
19. C.E. Whibley Antiesophageal cancer activity from Southern African marine organisms Ann. N. Y. Acad. Sci. 1056 2005 405 412
20. D.J. Faulkner Highlights of marine natural products chemistry (1972-1999) Nat. Prod. Rep. 17 2000 1 6
21. J.W. Blunt Marine natural products Nat. Prod. Rep. 28 2011 196 268
22. T.F. Molinsky Drug development from marine natural products Nat. Rev. Drug Discov. 8 2009 69 85
23. A.D. Kinghorn Discovery of natural product anticancer agents from biodiverse organisms Curr. Opin. Drug. Discov Devel. 12 2009 189 196
24. N.L. Daly NMR and protein structure in drug design: application to cyclotides and conotoxins Eur. Biophys. J. 40 2011 359 370
25. J. Uddin Cytotoxic labdane alkaloids from an ascidian Lissoclinum sp.: isolation, structure elucidation, and structure-activity relationship Bioorg. Med. Chem. 14 2006 6954 6961
26. R. Sakai Structure-activity relationships of the didemnins J. Med. Chem. 39 1996 2819 2834
27. M. Donia Natural combinatorial peptide libraries in cyanobacterial symbionts of marine ascidians Nat. Chem. Biol. 2 2006 729 735
28. P. Baumann Biology bacteriocyte-associated endosymbionts of plant sap-sucking insects Annu. Rev. Microbiol. 59 2005 155 189
29. M.J. Uddin Haterumaimides F-I, four new cytotoxic diterpene alkaloids from an ascidian Lissoclinum species J. Nat. Prod. 64 2001 1169 1173
30. Y. Miyata Ecdysteroids from the Antarctic tunicate Synoicum adareanum J. Nat. Prod. 70 2007 1859 1864
31. P.J. Sung Hydroperoxysterols from the tunicate Eudistoma sp. Chem. Pharm. Bull. 55 2007 666 668
32. K.B. Glaser, and A.M. Mayer A renaissance in marine pharmacology: from preclinical curiosity to clinical reality Biochem. Pharmacol. 78 2009 440 448
33. R. Todd, and J. Lunec Molecular pathology and potential therapeutic targets in soft-tissue sarcoma Expert Rev. Anticancer Ther. 8 2008 939 948
34. E. Ulukaya Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay Chemotherapy 50 2004 43 50
35. A. Chwilkowska Death of tumor cells. Photodynamic reaction in apoptosis induction in cancer cells Pol. Merkur. Lekarski. 30 2011 45 48
36. C. Haanen, and I. Vermes Apoptosis and inflammation Mediators Inflamm. 4 1995 5 15
37. D.M. Spinner MTT growth assays in ovarian cancer Methods Mol. Med. 39 2001 175 177
38. T. Ogi Cytotoxic metabolites from the Okinawan ascidian Diplosoma virens Molecules 13 2008 595 602
39. A. Mayer, and K. Gustafson Marine pharmacology in 2005-2006: antitumor and cytotoxic compounds Eur. J. Can. 44 2008 2357 2387
40. J.A. Romashkova, and S.S. Makarov NF-kB is a target of AKT in anti-apoptotic PDGF signalling Nature 401 1999 86 90
41. T.T. Tan, and L.M. Coussens Humoral immunity, inflammation and cancer Curr. Opin. Immunol. 19 2007 209 216
42. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
43. S.R. Barthel Targeting selectins and selectin ligands in inflammation and cancer Expert Opin. Ther. Targets 11 2007 1473 1491
44. Y.J. Surh Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kB activation Mutat. Res. 480-481 2001 243 268
45. C.S. Xu Chondroitin sulfate extracted from the Styela clava tunic suppresses TNF-alpha-induced expression of inflammatory factors, VCAM-1 and iNOS by blocking Akt/NF-kappaB signal in JB6 cells Cancer Lett. 264 2008 93 100
46. E.O. Kozlowski Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin J. Thromb. Haemost. 9 2011 1807 1815
47. M. Einat Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients Exp. Hematol. 23 1995 1439 1444
48. M. Einat Potent antileukemic activity of the novel agents norsegoline and dibezine Clin. Cancer Res. 1 1995 823 829
49. M. Lishner Sensitivity of hematopoietic progenitors of acute myeloblastic leukemia to new compounds derived from marine organisms Leukemia 9 1995 1543 1548
50. L. Bouffier Functionalization of the A ring of pyridoacridine as a route toward greater structural diversity. Synthesis of octacyclic analogue of eilatin Bioorg. Med. Chem. Lett. 19 2009 4836 4838
51. M.C. Edler Inhibition of tubulin polymerization by vitilevuamide, a bicyclic marine peptide, at a site distinct from colchicine, the vinca alkaloids, and dolastatin 10 Biochem. Pharmacol. 63 2002 707 715
52. Z. Cruz-Monserrate Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis with their interactions with tubulin Mol. Pharmacol. 63 2003 1273 1280
53. G. Wang Diazonamide toxins reveal an unexpected function for ornithine delta-amino transferase in mitotic cell division Proc. Natl. Acad. Sci. U. S. A. 104 2007 2068 2073
54. M. Lachia, and C.J. Moody The synthetic challenge of diazonamide A, a macrocylic indole bis-oxazole marine natural product Nat. Prod. Rep. 25 2008 227 253
55. N.S. Williams Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity Proc. Natl. Acad. Sci. U. S. A. 104 2007 2074 2079
56. M.S. Donia Mollamides B and C, cyclic hexapeptides from the indonesian tunicate Didemnum molle J. Nat. Prod. 71 2008 941 945
57. R.H. Shoemaker The NCI60 human tumor cell line anticancer drug screen Nat. Rev. Can. 6 2006 813 823
58. D.R. Appleton Kottamides A-D: novel bioactive imidazolone-containing alkaloids from the New Zealand ascidian Pycnoclavella kottae J. Org. Chem. 67 2002 5402 5404
59. A.H. Cory Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture Cancer Commun. 3 1991 207 212
60. M. D'Incalci, and C.M. Galmarini A review of trabectedin (ET-743): a unique mechanism of action Mol. Cancer Ther. 9 2010 2157 2163
61. A. Mayer The odyssey of marine pharmaceuticals: a current pipeline perspective Trends Pharmacol. Sci. 31 2010 255 265
62. K.L. Rinehart Jr. Didemnins: antiviral and antitumor depsipeptides from a carribean tunicate Science 212 1981 933 935
63. H.G. Chun Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent Invest. New Drugs 4 1986 279 284
64. B.V. SirDeshpande, and P.L. Toogood Mechanism of protein synthesis inhibition by didemnin B in vitro Biochemistry 34 1995 9177 9184
65. K.L. Johnson Protein tyrosine kinase inhibitors prevent didemnin B-induced apoptosis in HL-60 cells FEBS Lett. 383 1996 1 5
66. B. Nuijen Pharmaceutical development of anticancer agents derived from marine sources Anticancer Drugs 11 2000 793 811
67. J.L. Urdiales Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates Cancer Lett. 102 1996 31 37
68. C. Cuevas Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B Org. Lett. 2 2000 2545 2548
69. C. Cuevas, and A. Francesch Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem Nat. Prod. Rep. 26 2009 322 337
70. E.J. Martinez, and E.J. Corey A new, more efficient, and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents Org. Lett. 2 2000 993 996
71. D. Soares Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells Mol. Cancer Ther. 10 2011 1481 1489
72. C. Gajdos, and A. Elias Trabectedin: safety and efficacy in the treatment of advanced sarcoma Clin. Med. Insights Oncol. 16 2011 35 43
73. F. Amant Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature Int. J. Gynecol. Cancer 19 2009 245 248
74. P. Schoffski Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma Expert Opin. Pharmacother. 9 2008 1609 1618
75. M. D'Incalci, and J. Jimeno Preclinical and clinical results with the natural marine product ET-743 Expert Opin. Investig. Drugs 12 2003 1843 1853
76. Y. Takebayashi Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair Nat. Med. 7 2001 961 966
77. C. Malochet-Grivois Effects in vitro of two marine substances, chlorolissoclimide and dichlorolissoclimide, on a non-small-cell bronchopulmonary carcinoma line (NSCLC-N6) Anticancer Drug Des. 7 1992 493 502
78. T. Ogi Isolation of C11 cyclopentenones from two didemnid species, Lissoclinum sp. and Diplosoma sp. Mar. Drugs 7 2009 816 832
79. A.D. Richardson, and C.M. Ireland A profile of the in vitro antitumor activity of lissoclinolide Toxicol. Appl. Pharmacol. 195 2004 55 61
80. T. Oda Cytotoxicity of lissoclibadins and lissoclinotoxins, isolated from a tropical ascidian Lissoclinum cf. badium, against human solid-tumor-derived cell lines Biol. Pharm. Bull. 30 2007 385 387
81. T.N. Makarieva Pibocin B, the first N-O-methylindole marine alkaloid, a metabolite from the Far-Eastern ascidian Eudistoma species J. Nat. Prod. 64 2001 1559 1561
82. P.C. Jimenez Cytotoxic activity of a dichloromethane extract and fractions obtained from Eudistoma vannamei (Tunicata: Ascidiacea) Comp. Biochem. Physiol. A: Mol. Integr. Physiol. 151 2008 391 398
83. M.A. Rashid New cytotoxic N-methylated beta-carboline alkaloids from the marine ascidian Eudistoma gilboverde J. Nat. Prod. 64 2001 1454 1456
84. N. Oku Shishijimicins A-C, novel enediyne antitumor antibiotics from the ascidian Didemnum proliferum (1) J. Am. Chem. Soc. 125 2003 2044 2045
85. R. Takeara Antileukemic effects of Didemnum psammatodes (Tunicata: Ascidiacea) constituents Comp. Biochem. Physiol. A: Mol. Integr. Physiol. 151 2008 363 369
86. L. Garrido Haouamines A and B: a new class of alkaloids from the ascidian Aplidium haouarianum J. Org. Chem. 68 2003 293 299
87. S.N. Fedorov Evaluation of cancer-preventive activity and structure-activity relationships of 3-demethylubiquinone Q2, isolated from the ascidian Aplidium glabrum, and it synthetic analogs Pharm. Res. 23 2006 70 81
88. H. Choi Tuberatolides, potent FXR antagonists from the Korean marine tunicate Botryllus tuberatus J. Nat. Prod. 74 2011 90 94
89. A. Aiello New bioactive sulfated metabolites from the Mediterranean tunicate Sidnyum turbinatum J. Nat. Prod. 64 2001 219 221
90. M.T. Davies-Coleman Stolonic acids A and B, new cytotoxic cyclic peroxides from an Indian Ocean ascidian Stolonica species J. Nat. Prod. 63 2000 1411 1413
91. D.A. Raftos, and A. Hutchinson Cytotoxicity reactions in the solitary tunicate Styelaplicata Dev. Comp. Immunol. 19 1995 463 471
92. Corey, E.J. Fellows of Harvard College (Cambridge, MA). Synthetic analogs of ecteinascidin 743, 6569859